angiogenesis inhibitory peptide

Angiogenesis inhibitory peptide, specifically the recombinant peptide known as HM-3, is an investigational anti-angiogenic agent developed by the Beijing Cancer Hospital (Beijing Institute for Cancer Research). It is a fusion peptide consisting of an Arg-Gly-Asp (RGD) sequence and a functional fragment of human endostatin. The RGD motif allows the peptide to specifically target integrins, such as integrin αvβ3 and αvβ5, which are highly expressed on the surface of proliferating vascular endothelial cells and certain tumor cells. By binding to these integrins, HM-3 inhibits endothelial cell migration, proliferation, and tube formation, thereby suppressing tumor-associated angiogenesis and subsequent tumor growth. Clinical development has focused on Phase I studies in China evaluating its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors, including lung, gastric, and liver cancers.

Other names

注射用血管抑制肽Vascular Inhibitory Peptide